Dehydrocannabifuran (DCBF) is an uncategorized cannabinoid compound. DCBF is almost not present in the cannabis sativa plant but can be synthesized from cannabidiol in yields of 29%. The cannabis plant consists of compounds that have ailment-treating benefits. Some of these compounds are psychoactive, while others are mild anti-effective agents. DCBF is one of these promising compounds even though its functions are yet to be discovered.

For the past 75 years, scientists worldwide have dedicated time to researching the cannabis plant. This occurs in labs, pharmaceutical companies, amongst others. The discovery of Robert Cahn led the world on a journey to understanding these compounds. While some fight the legal battle for the usage and the allowance of medical administration of marijuana, others are actively trying to discover more about the plant. This quest is what led to the discovery of dehydrocannabifuran.

The chemical composition of DCBF is unique in its construction. It contains 1 hydrogen bond donor, 2 hydrogen bond acceptors, and 5 rotatable bonds. With a surface area of 33.4A2, DCBF has a heavy atom count of 23 and a property complexity value of 418. It is formed through the process of decarbonation from the mother group CBF.

The possible future of this cannabinoid is a prediction that can’t be made wholesomely. Its functions are unknown, its therapeutic benefits yet to be discovered, and its discovery quantity from the cannabis plant is low compared with other compounds. There is a need for research, clinical trials and investigative findings into the cannabis plant for the functions of DCBF. Conclusively, there are no grey areas when it comes to DCBF. We just don’t know. 


DCBF’s function in the human body remains a myth since its discovery.  There is no clinical trial to tell how this compound behaves with the human body receptors. There is no test to show if it has psychoactive tendencies. We don’t know if it functions as a receptor blockage mechanism.

There are a few reasons for this lack of technical know-how. For one, the current tussle of legalization happening across the board is a bothering concern to stakeholders. Another reason is the lack of funds and research capital. Scientists need funds to advance their study of cannabinoids but won’t get without the appropriate and legal go ahead.


On the therapeutic benefits, we know that CGBV and CGBVA derivatives have their benefits. Some are psychoactive compounds that help with neurological pains and deficiencies, while some are natural pain blockers. The CBN family and its constituents are only slightly effective regarding medicinal psychotic areas due to their higher affinity for the CB1 and CB2 receptors. But we cannot say for a fact what therapeutic benefit DCBF holds and what potentials and medical advancements it will unlock.


  • Full molecular compound: 6-Methyl-9-isopropenyl-3-pentyldibenzofuran-1-ol
  • INCL: InChI=1S/C21H24O2/c1-5-6-7-8-15-11-17(22)20-18(12-15)23-21-14(4)9-10-16(13(2)3)19(20)21/h9-12,22H,2,5-8H2,1,3-4H3


PubChem [Internet]. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004-. PubChem Compound Summary for CID 59444381

Radwan MM, Ross SA, Slade D, Ahmed SA, Zulfiqar F, Elsohly MA. Isolation and characterization of new Cannabis constituents from a high potency variety.

National Library of Medicine:


Leave a Comment

Your email address will not be published. Required fields are marked *